Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/37996
Title: All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.
Authors: 
Mesh: 
Issue Date: 2018
Citation: Berenguer J, Gil-Martin Á, Jarrin I, Moreno A, Dominguez L, Montes M, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology. 2018 07;68(1):32-47
Abstract: We evaluated treatment outcomes in a prospective registry of human immunodeficiency virus/hepatitis C virus (HCV)-coinfected patients treated with interferon-free direct-acting antiviral agent-based therapy in hospitals from the region of Madrid between November 2014 and August 2016. We assessed sustained viral response at 12 weeks after completion of treatment and used multivariable logistic regression to identify predictors of treatment failure. We evaluated 2,369 patients, of whom 59.5% did not have cirrhosis, 33.9% had compensated cirrhosis, and 6.6% had decompensated cirrhosis. The predominant HCV genotypes were 1a (40.9%), 4 (22.4%), 1b (15.1%), and 3 (15.0%). Treatment regimens included sofosbuvir (SOF)/ledipasvir (61.9%), SOF plus daclatasvir (14.6%), dasabuvir plus ombitasvir/paritaprevir/ritonavir (13.2%), and other regimens (10.3%). Ribavirin was used in 30.6% of patients. Less than 1% of patients discontinued therapy owing to adverse events. The frequency of sustained viral response by intention-to-treat analysis was 92.0% (95% confidence interval, 90.9%-93.1%) overall, 93.8% (92.4%-95.0%) for no cirrhosis, 91.0% (88.8%-92.9%) for compensated cirrhosis, and 80.8% (73.7%-86.6%) for decompensated cirrhosis. The factors associated with treatment failure were male sex (adjusted odds ratio, 1.75; 95% confidence interval, 1.14-2.69), Centers for Diseases Control and Prevention category C (adjusted odds ratio, 1.65; 95% confidence interval, 1.12-2.41), a baseline cluster of differentiation 4-positive (CD4+) T-cell count <200/mm3 (adjusted odds ratio, 2.30; 95% confidence interval, 1.35-3.92), an HCV RNA load ≥800,000 IU/mL (adjusted odds ratio, 1.63; 95% confidence interval, 1.14-2.36), compensated cirrhosis (adjusted odds ratio, 1.35; 95% confidence interval, 0.96-1.89), decompensated cirrhosis (adjusted odds ratio, 2.92; 95% confidence interval, 1.76-4.87), and the use of SOF plus simeprevir, SOF plus ribavirin, and simeprevir plus daclatasvir.
PMID: 29377274
URI: https://hdl.handle.net/20.500.12530/37996
Rights: openAccess
Appears in Collections:Hospitales > H. U. Fundación Alcorcón > Artículos
Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Hospitales > H. U. 12 de Octubre > Artículos
Hospitales > H. U. Infanta Cristina > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Getafe > Artículos
Hospitales > H. U. Infanta Leonor > Artículos
Hospitales > H. U. Sureste > Artículos
Hospitales > H. U. Severo Ochoa > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos
Hospitales > H. U. de Fuenlabrada > Artículos
Hospitales > H. U. de Móstoles > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos
Hospitales > H. U. Henares > Artículos
Hospitales > H. U. Infanta Sofía > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos
Hospitales > H. El Escorial > Artículos
Hospitales > H. U. de Getafe > Artículos
Fundaciones e Institutos de Investigación > FIB H. U. Príncipe de Asturias > Artículos
Hospitales > H. U. Tajo > Artículos

Files in This Item:
File Description SizeFormat 
PMC6055848.pdf523.14 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.